Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
07:47am, Wednesday, 10'th Jun 2026
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08:22pm, Tuesday, 09'th Jun 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts
01:04pm, Tuesday, 09'th Jun 2026
Alnylam Pharmaceuticals NASDAQ: ALNY executives outlined the company's 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst S
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500
05:06pm, Monday, 08'th Jun 2026
The index added two companies on Friday, but more are likely to be added in the near future.
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
12:31pm, Thursday, 04'th Jun 2026
ALNY teams up with Inceptive in a deal worth up to $2B, using AI models and proprietary RNAi data to speed drug discovery and improve candidate selection.
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion
11:52am, Thursday, 04'th Jun 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock is up on Thursday after the company announced a strategic collaboration with Inceptive Nucleics, valued at up to $2 billion.
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
06:05pm, Wednesday, 03'rd Jun 2026
Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech Inceptive in a deal worth up to $2 billion to use AI to speed up discovery of RNA-based medicines.
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
04:45pm, Wednesday, 03'rd Jun 2026
CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models
Alnylam Issues 2025 Corporate Responsibility Report
08:30am, Tuesday, 19'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the D
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:40pm, Wednesday, 13'th May 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
04:15pm, Wednesday, 13'th May 2026
Alnylam Pharmaceuticals NASDAQ: ALNY Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in pa
Alnylam to Webcast Presentations at Upcoming Investor Conferences
08:00am, Thursday, 07'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
08:30am, Monday, 04'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients wit
